Huntington's disease: Towards disease modification - gaps and bridges, facts and opinions

Basal Ganglia

Volumn 2, Issue 4, 2012, Pages 241-248

  Reilmann, Ralf ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Huntington's disease Disease modification Clinical trial Endpoint Diagnosis

Indexed keywords

HISTONE DEACETYLASE; HUNTINGTIN;

ACETYLATION; ARTICLE; AUTOPHAGY; BIOMECHANICS; BRAIN ATROPHY; CELL REGENERATION; COHORT ANALYSIS; DEGENERATIVE DISEASE; ELECTRONIC MEDICAL RECORD; FUNDING; GENE LOCUS; GRIP STRENGTH; HUMAN; HUNTINGTON CHOREA; OBSERVATIONAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; RATING SCALE;

EID: 84879134175     PISSN: 22105336     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.baga.2012.09.004     Document Type: Article

References (136)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72(6):971-83 [see comments].
2. Semaka A, Creighton S, Warby S, Hayden MR. Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clin Genet 2006;70(4):283-94.
3. Lange H, Thorner G, Hopf A, Schroder KF. Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sci 1976;28(4): 401-25.
4. Walker FO. Huntington's disease. Lancet 2007;369(9557):218-28.
5. Hult S, Schultz K, Soylu R, Petersen A. Hypothalamic and neuroendocrine changes in Huntington's disease. Curr Drug Targets 2010;11(10):1237-49.
6. Aziz NA, Anguelova GV, Marinus J, Lammers GJ, Roos RA. Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease. Parkinsonism Relat Disord 2010;16(5):345-50.
7. Aziz NA, Anguelova GV, Marinus J, van Dijk JG, Roos RA. Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease. Eur J Neurol 2010;17(8):1068-74.
8. Kokmen E, Ozekmekci FS, Beard CM, O'Brien PC, Kurland LT. Incidence and prevalence of Huntington's disease in Olmsted County, Minnesota (1950 through 1989). Arch Neurol 1994;51(7):696-8.
9. Almqvist EW, Elterman DS, MacLeod PM, Hayden MR. High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. Clin Genet 2001;60(3):198-205.
10. Bombard Y, Veenstra G, Friedman JM, Creighton S, Currie L, Paulsen JS, et al. Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey. BMJ 2009;338:b2175. http://dx.doi.org/10.1136/bmj.b2175:b2175.
11. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009(3):CD006456.
12. Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opin Pharmacother 2007;8(2): 141-53.
13. Priller J, Ecker D, Landwehrmeyer B, Craufurd D. A Europe-wide assessment of current medication choices in Huntington's disease. Mov Disord 2008;23(12): 1788.
14. Bonelli RM, Beal MF. Huntington's disease. Handb Clin Neurol 2012;106: 507-26.
15. Venuto CS, McGarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington's disease. Mov Disord 2012;27(1):31-41.
16. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev 2009(3):CD006455.
17. Bates GP, Gonitel R. Mouse models of triplet repeat diseases. Mol Biotechnol 2006;32(2):147-58.
18. Munoz-Sanjuan I, Bates GP. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J Clin Invest 2011;121(2):476-83.
19. Neri C. Value of invertebrate genetics and biology to develop neuroprotective and preventive medicine in Huntington's disease. In: Lo DC, Hughes RE, editors. Neurobiology of Huntington's disease: applications to drug discovery. Boca Raton: CRC Press; 2011.
20. William YX, Gray M. Mouse models for validating preclinical candidates for Huntington's disease. In: Lo DC, Hughes RE, editors. Neurobiology ofHuntington's disease: applications to drug discovery. Boca Raton: CRC Press; 2011.
21. Morse RJ, Leeds JM, Macdonald D, Park L, Toledo-Sherman L, Pacifici R. Pharmaceutical development for Huntington's disease. In: Lo DC, Hughes RE, editors. Neurobiology of Huntington's disease: applications to drug discovery. Boca Raton: CRC Press; 2011.
22. Kwak SP, Wang JKT, Howland DS. Target validation for Huntington's disease. In: Lo DC, Hughes RE, editors. Neurobiology of Huntington's disease: applications to drug discovery. Boca Raton: CRC Press; 2011.
23. Varma H, Lo DC, Stockwell BR. High-throughput and high-content screening for Huntington's disease therapeutics. In: Lo DC, Hughes RE, editors. Neurobiology of Huntington's disease: applications to drug discovery. Boca Raton: CRC Press; 2011.
24. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011;10(1):83-98.
25. Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, et al. Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. PLoS Curr 2010;2:RRN1184.
26. Dorsey ER. Characterization of a large group of individuals with Huntington disease and their relatives enrolled in the COHORT study. PLoS One 2012;7(2):e29522.
27. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008;79(8):874-80.
28. Killoran A, Biglan K, Julian-Baros E, Yoritomoto N, Ross CA. Baseline characteristics of the PREQUEL cohort: an interventional trial in premanifest Huntington's disease. Mov Disord 2012;27(Suppl. 1):185 [Abstract].
29. Weir DW, Sturrock A, Leavitt BR. Development of biomarkers for Huntington's disease. Lancet Neurol 2011;10(6):573-90.
30. Reilmann R, Bohlen S, Kirsten F, Ringelstein EB, Lange HW. Assessment of involuntary choreatic movements in Huntington's disease - toward objective and quantitative measures. Mov Disord 2011;26(12):2267-73.
31. Reilmann R, Bohlen S, Klopstock T, Bender A, Weindl A, Saemann P, et al. Grasping premanifest Huntington's disease - shaping new endpoints for new trials. Mov Disord 2010;25(16):2858-62.
32. Bechtel N, Scahill RI, Rosas HD, Acharya T, van den Bogaard SJ, Jauffret C, et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology 2010;75(24):2150-60.
33. Reilmann R, Bohlen S, Klopstock T, Bender A, Weindl A, Saemann P, et al. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease. Mov Disord 2010;25(13):2195-202.
34. Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006;63(6):883-90.
35. Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8(9):791-801.
36. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10(1):31-42.
37. Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012;11(1):42-53.
38. Shoulson I, Young AB. Milestones in Huntington disease. Mov Disord 2011; 26(6):1127-33.
39. Dorsey R, Shoulson I. Huntington's disease: clinical experimental therapeutics. In: Lo DC, Hughes PE, editors. Neurobiology of Huntington's disease: applications to drug discovery. Boca Raton: CRC Press; 2011.
40. Johnson CD, Davidson BL. Huntington's disease: progress toward effective disease-modifying treatments and a cure. Hum Mol Genet 2010; 19(R1):R98-R102.
41. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A 2005;102(16): 5820-5.
42. Machida Y, Okada T, Kurosawa M, Oyama F, Ozawa K, Nukina N. RAAVmediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem Biophys Res Commun 2006;343(1):190-7.
43. Difiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A 2007;104(43):17204-9.
44. Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, et al. Nonallelespecific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 2009;17(6): 1053-63.
45. Pfister EL, Zamore PD. Huntington's disease: silencing a brutal killer. Exp Neurol 2009;220(2):226-9.
46. Sah DW, Aronin N. Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest 2011;121(2):500-7.
47. Meghan S, Aronin N. RNA- and DNA-based therapies for Huntington's disease. In: Lo DC, Hughes RE, editors. Neurobiology of Huntington's disease: applications to drug discovery. Boca Raton: CRC Press; 2011.
48. Reiner A, Dragatsis I, Zeitlin S, Goldowitz D. Wild-type huntingtin plays a role in brain development and neuronal survival. Mol Neurobiol 2003;28(3): 259-76.
49. Aronin N. Target selectivity in mRNA silencing. Gene Ther 2006;13(6): 509-16.
50. Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, Difiglia M, et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 2009;19(9):774-8.
51. Hu J, Matsui M, Gagnon KT, Schwartz JC, Gabillet S, Arar K, et al. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 2009;27(5):478-84.
52. Hu J, Matsui M, Corey DR. Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Ann N Y Acad Sci 2009;1175:24-31.
53. Denovan-Wright EM, Rodriguez-Lebron E, Lewin AS, Mandel RJ. Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo. Neurobiol Dis 2008;29(3):446-55.
54. Boudreau RL, Spengler RM, Davidson BL. Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol Ther 2011;19(12):2169-77.
55. Southwell AL, Patterson PH. Gene therapy in mouse models of Huntington disease. Neuroscientist 2011;17(2):153-62.
56. McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther 2011;19(12): 2152-62.
57. Jacobsen JC, Bawden CS, Rudiger SR, McLaughlan CJ, Reid SJ, Waldvogel HJ, et al. An ovine transgenic Huntington's disease model. Hum Mol Genet 2010;19(10):1873-82.
58. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A. Huntington's disease: the current state of research with peripheral tissues. Exp Neurol 2009;219(2):385-97.
59. van der Burg JM, Bjorkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol 2009;8(8):765-74.
60. Krainc D. Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases. Arch Neurol 2010;67(4):388-92.
61. Martinez-Vicente M, Talloczy Z, Wong E, Tang G, Koga H, Kaushik S, et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci 2010;13(5):567-76.
62. Sarkar S, Rubinsztein DC. Huntington's disease: degradation of mutant huntingtin by autophagy. FEBS J 2008;275(17):4263-70.
63. Zheng S, Clabough EB, Sarkar S, Futter M, Rubinsztein DC, Zeitlin SO. Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice. PLoS Genet 2010;6(2):e1000838.
64. Ravikumar B, Rubinsztein DC. Role of autophagy in the clearance of mutant huntingtin: a step towards therapy? Mol Aspects Med 2006;27(5-6): 520-7.
65. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004;36(6): 585-95.
66. Williams A, Sarkar S, Cuddon P, Ttofi EK, Saiki S, Siddiqi FH, et al. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat Chem Biol 2008;4(5):295-305.
67. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 2007;282(8):5641-52.
68. Tsvetkov AS, Miller J, Arrasate M, Wong JS, Pleiss MA, Finkbeiner S. A smallmolecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. Proc Natl Acad Sci U S A 2010;107(39):16982-7.
69. Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, et al. Global changes to the ubiquitin system in Huntington's disease. Nature 2007;448(7154):704-8.
70. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 2008;15(6):558-66.
71. Ehrnhoefer DE, Duennwald M, Markovic P, Wacker JL, Engemann S, Roark M, et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet 2006;15(18):2743-51.
72. Arrasate M, Finkbeiner S. Protein aggregates in Huntington's disease. Exp Neurol 2012;238(1):1-11.
73. Wang Y, Lin F, Qin ZH. The role of post-translational modifications of huntingtin in the pathogenesis of Huntington's disease. Neurosci Bull 2010;26(2):153-62.
74. Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, Hayden MR. Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci 2009;40(2):121-7.
75. Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, et al. IKK phosphorylates huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol 2009;187(7):1083-99.
76. Aiken CT, Steffan JS, Guerrero CM, Khashwji H, Lukacsovich T, Simmons D, et al. Phosphorylation of threonine 3: implications for huntingtin aggregation and neurotoxicity. J Biol Chem 2009;284(43):29427-36.
77. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001;413(6857):739-43.
78. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 2009;32(11): 591-601.
79. Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, Thompson LM, et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet 2008;17(23): 3767-75.
80. Zhang F, Wang S, Gan L, Vosler PS, Gao Y, Zigmond MJ, et al. Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol 2011;95(3):373-95.
81. Pereira CV, Lebiedzinska M, Wieckowski MR, Oliveira PJ. Regulation and protection of mitochondrial physiology by sirtuins. Mitochondrion 2012;12(1):66-76.
82. Zhong L, Mostoslavsky R. Fine tuning our cellular factories: sirtuins in mitochondrial biology. Cell Metab 2011;13(6):621-6.
83. Jiang M, Wang J, Fu J, Du L, Jeong H, West T, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med 2011;18(1):153-8.
84. Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 2011;18(1):159-65.
85. La Spada AR. Finding a sirtuin truth in Huntington's disease. Nat Med 2012;18(1):24-6.
86. Rosser AE, Dunnett SB. Cell transplantation for Huntington's disease. Lancet Neurol 2006;5(4):284-5.
87. Lindvall O, Barker RA, Brustle O, Isacson O, Svendsen CN. Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell 2012;10(2): 151-5.
88. Dunnett SB, Rosser AE. Cell transplantation for Huntington's disease: should we continue? Brain Res Bull 2007;72(2-3):132-47.
89. Clelland CD, Barker RA, Watts C. Cell therapy in Huntington disease. Neurosurg Focus 2008;24(3-4):E9.
90. Bachoud-Levi AC, Gaura V, Brugieres P, Lefaucheur JP, Boisse MF, Maison P, et al. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 2006;5(4): 303-9.
91. Cicchetti F, Saporta S, Hauser RA, Parent M, Saint-Pierre M, Sanberg PR, et al. Neural transplants in patients with Huntington's disease undergo diseaselike neuronal degeneration. Proc Natl Acad Sci U S A 2009;106(30):12483-8.
92. Dunnett SB, Rosser AE. Cell-based treatments for Huntington's disease. Int Rev Neurobiol 2011;98:483-508.
93. Freeman TB, Cicchetti F, Bachoud-Levi AC, Dunnett SB. Technical factors that influence neural transplant safety in Huntington's disease. Exp Neurol 2011;227(1):1-9.
94. Olson SD, Pollock K, Kambal A, Cary W, Mitchell GM, Tempkin J, et al. Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease. Mol Neurobiol 2012;45(1):87-98.
95. An MC, Zhang N, Scott G, Montoro D, Wittkop T, Mooney S, et al. Genetic Correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012;11(2):253-63.
96. Han DW, Tapia N, Hermann A, Hemmer K, Hoing S, Arauzo-Bravo MJ, et al. Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell Stem Cell 2012;10(4):465-72.
97. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996;11(2):136-42.
98. de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011;10(12):1049-57.
99. Huntington Study Group. Randomized controlled trial of ethyleicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 2008;65(12):1582-9.
100. Landwehrmeyer GB, Dubois B, de Yebenes JG, Kremer B, Gaus W, Kraus PH, et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007;62(3):262-72.
101. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66(3):366-72.
102. Paulsen JS, Wang C, Duff K, Barker R, Nance M, Beglinger L, et al. Challenges assessing clinical endpoints in early Huntington disease. Mov Disord 2010;25(15):2595-603.
103. Vaccarino AL, Sills T, Anderson KE, Biglan K, Borowsky B, Giuliano J, et al. Assessment of motor symptoms and functional impact in prodromal and early Huntington disease. PLoS Curr 2011;2:RRN1244.
104. Kieburtz K, Venuto C. TRACK-HD: both promise and disappointment. Lancet Neurol 2012;11(1):24-5.
105. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004;1(2):189-95.
106. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EPJ. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44(6):559-77.
107. Myers RH, Vonsattel JP, Stevens TJ, Cupples LA, Richardson EP, Martin JB, et al. Clinical and neuropathologic assessment of severity in Huntington's disease. Neurology 1988;38(3):341-7.
108. Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994;44(5):823-8.
109. Aylward EH, Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 1996;53(12):1293-6.
110. Aylward EH, Anderson NB, Bylsma FW, Wagster MV, Barta PE, Sherr M, et al. Frontal lobe volume in patients with Huntington's disease. Neurology 1998;50(1):252-8.
111. Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH, et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002;58(5):695-701.
112. Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov Disord 2006;21(9):1317-25.
113. Nopoulos P, Magnotta VA, Mikos A, Paulson H, Andreasen NC, Paulsen JS. Morphology of the cerebral cortex in preclinical Huntington's disease. Am J Psychiatry 2007;164(9):1428-34.
114. Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008;131(Pt. 4):1057-68.
115. Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, et al. Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis 2010;40(3):544-54.
116. Aylward EH, Li Q, Stine OC, Ranen N, Sherr M, Barta PE, et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997;48(2):394-9.
117. Aylward EH, Codori AM, Rosenblatt A, Sherr M, Brandt J, Stine OC, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord 2000;15(3):552-60 [in process citation].
118. Aylward EH, Nopoulos PC, Ross CA, Langbehn DR, Pierson RK, Mills JA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2011;82(4):405-10.
119. Scahill RI, Hobbs NZ, Say MJ, Bechtel N, Henley SM, Hyare H, et al. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Hum Brain Mapp 2011:10.
120. Sitek EJ, Soltan W, Wieczorek D, Schinwelski M, Robowski P, Reilmann R, et al. Self-awareness of motor dysfunction in patients with Huntington's disease in comparison to Parkinson's disease and cervical dystonia. J Int Neuropsychol Soc 2011;17(5):788-95.
121. Gordon AM, Quinn L, Reilmann R, Marder K. Coordination of prehensile forces during precision grip in Huntington's disease. Exp Neurol 2000;163(1):136-48.
122. Reilmann R, Rumpf S, Beckmann H, Koch R, Ringelstein EB, Lange HW. Huntington's disease: objective assessment of posture - a link between motor and functional deficits. Mov Disord 2012;27(4):555-9.
123. Bohlen S, Ekwall C, Hellstrom K, Vesterlin H, Bjornefur M, Wiklund L et al. Physical therapy in Huntington's disease - toward objective assessments? Eur J Neurol 2012 (in press).
124. Grimbergen YA, Knol MJ, Bloem BR, Kremer BP, Roos RA, Munneke M. Falls and gait disturbances in Huntington's disease. Mov Disord 2008;23(7):970-6.
125. Rao AK, Muratori L, Louis ED, Moskowitz CB, Marder KS. Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease. Mov Disord 2008;23(8):1100-7.
126. Hinton SC, Paulsen JS, Hoffmann RG, Reynolds NC, Zimbelman JL, Rao SM. Motor timing variability increases in preclinical Huntington's disease patients as estimated onset of motor symptoms approaches. J Int Neuropsychol Soc 2007;13(3):539-43.
127. Reilmann R, Kirsten F, Quinn L, Henningsen H, Marder K, Gordon AM. Objective assessment of progression in Huntington's disease: a 3-year followup study. Neurology 2001;57(5):920-4.
128. Biglan KM. Tapping in Huntington disease: a path forward to preventive therapies? Neurology 2010;75(24):2142-3.
129. Dumas EM, van den Bogaard SJ, Ruber ME, Reilmann R, Stout JC, Craufurd D, et al. Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. Hum Brain Mapp 2012;33(1):203-12.
130. Sturrock A, Laule C, Decolongon J, Dar SR, Coleman AJ, Creighton S, et al. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology 2010;75(19):1702-10.
131. Penney JBJ, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41(5):689-92 [see comments].
132. Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, et al. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord 2009;24(12):1763-72.
133. Paulson HL, Albin RL. Huntington's disease: clinical features and routes to therapy. In: Lo DC, Hughes RE, editors. Neurobiology of Huntington's disease: applications to drug discovery. Boca Raton: CRC Press; 2011.
134. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med 2004(Suppl. 10):S10-7.
135. Ross CA, Poirier MA. Opinion: what is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol 2005;6(11):891-8.
136. Ehrnhoefer DE, Wong BK, Hayden MR. Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. Nat Rev Drug Discov 2011;10(11):853-67.